open access

Vol 50, No 1 (2019)
Original Research Article / Praca Oryginalna
Published online: 2019-05-08
Submitted: 2018-08-08
Get Citation

Stem Cell Transplantation in Pediatric Patients with Myelodysplastic Syndrome at a Single Institution

Suleimman Al-Sweedan, Mona Alassiri, Ghaida Aljamal, Rafat Jafri, Amal Alseraihy, Khawar Siddiqui
DOI: 10.2478/ahp-2019-0005
·
Acta Haematol Pol 2019;50(1):25-31.

open access

Vol 50, No 1 (2019)
Original Research Article / Praca Oryginalna
Published online: 2019-05-08
Submitted: 2018-08-08

Abstract

In MDS, the bone marrow produces abnormal, immature blood cells called blast cells. Imprecise, in half of pediatric MDS, blast count is normal. A retrospective observational study was conducted to review the outcome of our HCT in pediatric patients with MDS. Record of 35 MDS patients after BMT, 1993-2016, were reviewed. Median age at transplant was 4 yrs (0.8-14.8) and median time to transplant from diagnosis 8.1 (2.3-102.5) months. TRM was 17.1% (6); [low risk (LR) = 5 (19.2%) and high risk (HR) = 1 (11.1%)] MDS group succumbed within first 100 days. The rest were fully engrafted; [low risk = 21 (72.4%) and high risk = 8 (27.6%)]. Primary and secondary graft failure was observed in one patient each (2.9%). VOD was seen in 2 patients (5.7%) and 5 (14.3%) had hemorrhagic cystitis. With a median follow-up of 112.4 months and 12 events of mortality, 3-years OS was 68.1% ± 8.0%. No significant risk factor including age, time to transplant, disease risk group, gender, conditioning regimen, source of stem cells, or a GvHD through uni- or multi-variable analyses were found to be associated with OS. Bu/Cy/±ATG conditioning regimen showed a trend of superiority for OS and EFS in our small series. The relapse incidence in our cohort was 11.5% in LR MDS.

Abstract

In MDS, the bone marrow produces abnormal, immature blood cells called blast cells. Imprecise, in half of pediatric MDS, blast count is normal. A retrospective observational study was conducted to review the outcome of our HCT in pediatric patients with MDS. Record of 35 MDS patients after BMT, 1993-2016, were reviewed. Median age at transplant was 4 yrs (0.8-14.8) and median time to transplant from diagnosis 8.1 (2.3-102.5) months. TRM was 17.1% (6); [low risk (LR) = 5 (19.2%) and high risk (HR) = 1 (11.1%)] MDS group succumbed within first 100 days. The rest were fully engrafted; [low risk = 21 (72.4%) and high risk = 8 (27.6%)]. Primary and secondary graft failure was observed in one patient each (2.9%). VOD was seen in 2 patients (5.7%) and 5 (14.3%) had hemorrhagic cystitis. With a median follow-up of 112.4 months and 12 events of mortality, 3-years OS was 68.1% ± 8.0%. No significant risk factor including age, time to transplant, disease risk group, gender, conditioning regimen, source of stem cells, or a GvHD through uni- or multi-variable analyses were found to be associated with OS. Bu/Cy/±ATG conditioning regimen showed a trend of superiority for OS and EFS in our small series. The relapse incidence in our cohort was 11.5% in LR MDS.

Get Citation

Keywords

myelodysplatic syndromes outcome; children; hematopoietic cell transplantation

About this article
Title

Stem Cell Transplantation in Pediatric Patients with Myelodysplastic Syndrome at a Single Institution

Journal

Acta Haematologica Polonica

Issue

Vol 50, No 1 (2019)

Pages

25-31

Published online

2019-05-08

DOI

10.2478/ahp-2019-0005

Bibliographic record

Acta Haematol Pol 2019;50(1):25-31.

Keywords

myelodysplatic syndromes outcome
children
hematopoietic cell transplantation

Authors

Suleimman Al-Sweedan
Mona Alassiri
Ghaida Aljamal
Rafat Jafri
Amal Alseraihy
Khawar Siddiqui

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl